Menu
Peptide Database
Results
No peptides found
Featured

Use search to browse all 100+ peptides

LL-37

Cathelicidin, hCAP-18, FALL-39, CAP-18

Quick Stats
Studies 2230
Trials 95
2018 pubmed 27 citations

Urinary antimicrobial peptides: Potential novel biomarkers of obstructive uropathy.

Gupta. S S; Jackson. A R AR; DaJusta. D G DG; McLeod. D J DJ; Alpert. S A SA; Jayanthi. V R VR; McHugh. K K; Schwaderer. A R AR; Becknell. B B; Ching. C B CB

Key Findings

  • Urinary LL-37, BD-1, NGAL, and HIP/PAP levels were significantly higher in children with obstructive uropathy compared to controls
  • These peptide elevations correlated with the presence of urinary obstruction and could predict it with statistical significance
  • The study is the first to report increased BD-1 and HIP/PAP in non‑infectious urinary tract obstruction

Practical Outcomes

  • For most biohackers this information isn’t directly useful; it simply shows that LL-37 rises when the urinary tract is blocked, a condition not typically monitored or treated by self‑experiments. No dosage, supplement, or protocol recommendations arise from these findings.

Summary

A small study measured LL-37 and other antimicrobial peptides in the urine of children with kidney‑pipe blockage and found they were higher than in healthy kids, indicating these peptides could serve as markers of urinary tract stress, but the research does not provide any actionable advice for health optimization.

Abstract

Antimicrobial peptides (AMPs) have historically been evaluated for their role in protecting against uropathogens. However, there is mounting evidence to support their expression in noninfectious injury, with unclear meaning as to their function. It is possible that AMPs represent urothelial injury. Urinary tract obstruction is known to alter the urothelium; however, AMPs have not been evaluated for expression in this noninfectious injury. A pilot study to compare urinary AMP expression in children undergoing surgical intervention for ureteropelvic junction obstruction (UPJO) with nonobstructed controls. Bladder urine was collected from consenting/assenting pediatric patients with UPJO at intervention. Control bladder urines were obtained from age-matched and sex-matched healthy children without known obstruction or infection. Enzyme-linked immunosorbent assays were run for the following AMPs: β defense 1 (BD-1), neutrophil gelatinase-associated lipocalin (NGAL), cathelicidin (LL-37), hepatocarcinoma-intestine-pancreas/pancreatitis-associated protein (HIP/PAP), and human α defensin 5 (HD-5); and normalized to urine creatinine. Results were analyzed with Student's t-test or Mann-Whitney U test, when appropriate, and receiver operating characteristic curves. A P-value of <0.05 was considered significant. Thirty bladder urine samples were obtained from children with UPJO at the time of decompressive intervention. Mean patient age was 4.7 years (range 0.3-18.4); 20 (67%) patients were male. Fifteen bladder urine samples were obtained from age-matched and sex-matched controls. Urinary AMP levels were significantly higher in UPJO patients than controls for BD-1 (P = 0.015), NGAL (P < 0.001), LL-37 (P < 0.001), and HIP/PAP (P = 0.046). Optimal threshold values of these AMPs were determined, with each demonstrating significant odds ratios of predicting urinary obstruction. Certain urinary AMPs are altered even in noninfectious urinary tract pathology. This represents a novel induction of AMP expression, as the current study is the first to report elevations in BD-1 and HIP/PAP in urinary tract obstruction. This suggests other roles for these AMPs outside of their antimicrobial properties, and likely is a reflection of the urothelial and tubular stress resulting from obstructive uropathy. Induction of AMPs BD-1, NGAL, LL-37, and HIP/PAP was found to occur in urinary tract obstruction. Further evaluation of AMP expression as a biomarker of uroepithelial injury outside of infection is indicated.

Study Information

Provider

pubmed

Year

2018

Date

2018-03-29T00:00:00.000Z

DOI

10.1016/j.jpurol.2018.03.006

Citations

27

References

25